Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinibCamillo Porta, Lucia Bonomi, Chiara Paglino et al.|Clinical and Experimental Medicine|2007Cited by 146
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinibCamillo Porta, Cinzia Canipari, Chiara Paglino et al.|Kidney International|2010Cited by 99
Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesCamillo Porta, Emilio Bajetta, Giuseppe Procopio et al.|British Journal of Urology|2011Cited by 87
Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma PatientsCamillo Porta, Mara De Amici, Chiara Paglino et al.|Oncology|2012Cited by 78
Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patientsCamillo Porta, Luciano Mutti, Matteo Zimatore et al.|Lung Cancer|2005Cited by 51